ReviewJournal of the Egyptian National Cancer Institute2025
The role of stem cells in precision medicine: next-generation cancer treatment.
Review in Journal of the Egyptian National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrecision medicine has transformed oncology by tailoring treatments to the molecular and genetic characteristics of individual tumors. Stem cell-based strategies hold unique potential to complement these approaches by enabling regenerative support, targeted delivery of therapeutics, and novel models for drug screening.
methodsThis review synthesizes current evidence on the integration of stem cell biology into precision cancer therapy, highlighting advances in tumor profiling, next-generation sequencing (NGS), and genome editing that enable personalized interventions.
resultsEmerging applications include engineered stem cells for selective delivery of oncolytic agents, immune modulation through stem cell-derived platforms, and the use of induced pluripotent stem cells (iPSCs) for modeling tumor heterogeneity. Advances in NGS are accelerating tumor-specific profiling, facilitating gene editing of stem cells, and refining patient selection for therapy. CHALLENGES: Despite progress, translational barriers remain, including risks of tumorigenicity, ethical concerns, high costs, immune rejection, and limited large-scale clinical validation.
conclusionStem cell-based precision oncology is a rapidly evolving field with significant promise. Future directions include integrating NGS-driven tumor profiling with engineered stem cells, optimizing safety through gene-editing technologies, and advancing clinical trials to establish efficacy. These efforts could reshape the landscape of individualized cancer care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.